CGRP (Calcitonin Gene-Related Peptide): Vasodilation Research, Migraine Mechanisms & Antagonist Development

CGRP: One of the Most Potent Vasodilator Peptides Known

Calcitonin gene-related peptide (CGRP) is a 37-amino-acid neuropeptide produced by alternative splicing of the calcitonin gene (CALCA). It exists in two isoforms — α-CGRP, predominantly expressed in sensory neurons of the trigeminal and dorsal root ganglia, and β-CGRP, found mainly in the enteric nervous system. α-CGRP is the isoform that dominates vascular and pain research.

When released from perivascular sensory nerve endings, CGRP produces vasodilation that is 10 to 1,000 times more potent than other vasodilatory agents like acetylcholine or substance P, depending on the vascular bed studied. This extraordinary potency made CGRP one of the first neuropeptides identified as a direct link between the sensory nervous system and vascular function.

Receptor Pharmacology: The CLR/RAMP1 Complex

CGRP does not bind a conventional single-protein receptor. Instead, it signals through a heterodimeric complex consisting of the calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1). Without RAMP1, CLR cannot traffic to the cell surface or bind CGRP with high affinity. This requirement for a co-receptor makes the CGRP system pharmacologically unique and explains why developing selective antagonists proved challenging for decades.

Once CGRP engages the CLR/RAMP1 complex, it triggers Gαs-coupled cAMP accumulation, activating protein kinase A (PKA) and downstream vasodilatory cascades in smooth muscle cells. In sensory neurons, CGRP signaling also modulates pain sensitization pathways, lowering activation thresholds and amplifying nociceptive transmission. This dual vascular-neural action is central to its role in migraine pathophysiology.

CGRP and Migraine: From Observation to Mechanism

The connection between CGRP and migraine was established through a series of elegant experiments in the 1990s and 2000s. Goadsby and Edvinsson demonstrated that CGRP levels in jugular venous blood rise sharply during migraine attacks. Intravenous CGRP infusion in migraine-susceptible individuals triggers attacks that are clinically indistinguishable from spontaneous episodes. And CGRP receptor antagonists abort these induced attacks.

The mechanistic picture that emerged places CGRP at the center of the trigeminovascular system — the neural circuit connecting trigeminal sensory fibers to meningeal blood vessels. During a migraine event, cortical spreading depression or other triggers activate trigeminal afferents, releasing CGRP at meningeal vessel terminals. The resulting vasodilation, neurogenic inflammation, and peripheral sensitization produce the characteristic pulsating headache, photophobia, and allodynia.

What made this discovery transformative was its mechanistic specificity. Unlike triptans, which constrict blood vessels systemically and carry cardiovascular risk, targeting CGRP or its receptor could block migraine signaling without direct vasoconstrictive effects.

Anti-CGRP Therapeutics: Monoclonal Antibodies and Gepants

Two classes of anti-CGRP agents have reached the clinic. Monoclonal antibodies — erenumab (targeting the CLR/RAMP1 receptor), fremanezumab, galcanezumab, and eptinezumab (targeting the CGRP ligand) — provide sustained CGRP pathway blockade with monthly or quarterly injections. These agents have demonstrated consistent reductions in monthly migraine days across multiple Phase 3 programs, with favorable safety profiles that reflect the selectivity of the CGRP mechanism.

Small-molecule CGRP receptor antagonists, called gepants, offer oral alternatives. Ubrogepant, rimegepant, and atogepant are approved for acute or preventive migraine use. Unlike the first-generation gepant telcagepant, which was discontinued due to hepatotoxicity, current gepants show clean liver safety in clinical data accumulated through 2025.

The existence of both antibody and small-molecule approaches targeting the same pathway provides researchers with complementary tools for studying CGRP biology — long-acting depot blockade versus acute, reversible antagonism.

Beyond Migraine: CGRP in Cardiovascular and Inflammatory Research

CGRP’s role extends beyond headache neurobiology. In cardiovascular research, CGRP has been studied as a protective mediator against hypertension and ischemia-reperfusion injury. Rodent models of myocardial infarction show that exogenous CGRP administration reduces infarct size and improves post-ischemic cardiac function, likely through its vasodilatory and anti-inflammatory properties.

In wound healing models, CGRP promotes angiogenesis and modulates inflammatory cell recruitment. Its expression in skin sensory nerves links cutaneous innervation to tissue repair — a phenomenon termed “neurogenic wound healing.” Diabetic neuropathy, which depletes sensory nerve CGRP stores, is associated with impaired wound closure, suggesting a mechanistic link between neuropeptide loss and chronic wound pathology.

Inflammatory bowel disease models also show CGRP involvement. Its immunomodulatory effects — generally anti-inflammatory in the gut — position CGRP as a potential mediator in the gut-brain axis, though this research remains early-stage.

Research Frontiers

Key open questions include whether long-term CGRP blockade in migraine carries cardiovascular consequences (given CGRP’s protective vascular role), whether CGRP agonists could be developed for conditions where enhanced vasodilation is beneficial, and how CGRP interacts with other sensory neuropeptides like substance P and pituitary adenylate cyclase-activating peptide (PACAP) in complex pain circuits. The CGRP field in 2026 sits at the intersection of neuroscience, vascular biology, and immunology — a rich territory for peptide researchers.

Disclaimer: This content is intended for research purposes only and is not meant to constitute medical advice.